CD274 and non-small cell lung carcinoma: In a retrospective study that included 221 patients with advanced NSCLC and high PD-L1 expression (≥50%) who received first-line pembrolizumab, low levels of dNLR (<2.6), compared to high levels (≥2.6), were found to be associated with a significantly higher objective response rate (52.4% vs. 24.7%, p < 0.001) and longer median PFS (10.4 vs. 3.4 months, p < 0.001) and OS (36.6 vs. 9.8 months, p < 0.001).